Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
30.64
-0.11 (-0.36%)
Mar 7, 2025, 4:00 PM EST - Market closed
Janux Therapeutics Revenue
In the year 2024, Janux Therapeutics had annual revenue of $10.59M with 30.99% growth.
Revenue (ttm)
$10.59M
Revenue Growth
+30.99%
P/S Ratio
155.55
Revenue / Employee
$130,716
Employees
81
Market Cap
1.81B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
JANX News
- 8 days ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire
- 6 weeks ago - Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire
- 2 months ago - Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data - Seeking Alpha
- 2 months ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 3 months ago - Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
- 3 months ago - Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 3 months ago - Janux Therapeutics Announces Proposed Public Offering - Business Wire
- 3 months ago - Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Benzinga